These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12914117)

  • 1. [Use of monoclonal antibodies to plague microbe antigens at the early stage of infection in white mice for enhancement of the late streptomycin and doxycycline treatment].
    Ryzhko IV; Tsuraeva RI; Alekseeva LP; Shcherbaniuk AI; Mishan'kin MB
    Antibiot Khimioter; 2003; 48(3):21-5. PubMed ID: 12914117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Doxycycline in the prevention of experimental plague induced by plague microbe variants].
    Samokhodkina ED; Ryzhko IV; Shcherbaniuk AI; Kasatkina IV; Tsuraeva RI; Zhigalova TA
    Antibiot Khimioter; 1992 Nov; 37(11):26-8. PubMed ID: 1300930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of plague prophylaxis with streptomycin, tetracycline, and rifampicin in simultaneous immunization of white mice by resistant EV NRIEG strain].
    Ryzhko IV; Tsuraeva RI; Moldavan IA; Shcherbaniuk AI
    Antibiot Khimioter; 2004; 49(1):17-21. PubMed ID: 15164519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cefoperazone in the prevention and treatment of experimental plague caused by typical and fraction-free pathogen strains in white mice].
    Pasiukov VV; Ryzhko IV; Tsuraeva RI; Samokhodkina ED; Roshchina NV
    Antibiot Khimioter; 1994 Aug; 39(8):37-40. PubMed ID: 7695439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.
    Hill J; Copse C; Leary S; Stagg AJ; Williamson ED; Titball RW
    Infect Immun; 2003 Apr; 71(4):2234-8. PubMed ID: 12654847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen].
    Samokhodkina ED; Shcherbaniuk AI; Ryzhko IV; Tsuraeva RI; Skalyga EIu
    Antibiot Khimioter; 2002; 47(3):26-9. PubMed ID: 16127904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe].
    Shcherbaniuk AI; Liukshina EIu; Ryzhko IV; Smorodinova IuV
    Antibiot Khimioter; 2006; 51(1):7-10. PubMed ID: 16734358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Heme Oxygenase Expression by Cobalt Protoporphyrin Treatment Prevents Pneumonic Plague Caused by Inhalation of
    Willix JL; Stockton JL; Olson RM; Anderson PE; Anderson DM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Isepamycin in prophylaxis and treatment of experimental plague due to FI+ and FI- variants of plague microbe].
    Smorodinova IuV; Shcherbaniuk AI; Ryzhko IV; Moldavan IA
    Antibiot Khimioter; 2005; 50(8-9):23-6. PubMed ID: 17016907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylactic use of ceftriaxone in combination with F I antigen immunization in studies on uninbred albino mice infected by Yersinia pestis. Antiplague immunity development].
    Ryzhko IV; Moldavan IA; Tsuraeva RI; Shcherbaniuk AI
    Antibiot Khimioter; 2006; 51(9-10):8-12. PubMed ID: 18030785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparative study of fluoroquinolones and 3rd-generation cephalosporins in the prevention and treatment of experimental plague caused by Yersinia pestis strains typical and serologically atypical with respect to F1].
    Ryzhko IV; Shcherbaniuk AI; Tsuraeva RI; Samokhodkina ED; Kasatkina IV; Tsetskhladze NS; Pasiukov VV; Roshchina NV
    Antibiot Khimioter; 1997; 42(1):12-6. PubMed ID: 9221699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.
    Russell P; Eley SM; Bell DL; Manchee RJ; Titball RW
    J Antimicrob Chemother; 1996 Apr; 37(4):769-74. PubMed ID: 8722542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
    Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
    Heine HS; Louie A; Sorgel F; Bassett J; Miller L; Sullivan LJ; Kinzig-Schippers M; Drusano GL
    J Infect Dis; 2007 Sep; 196(5):782-7. PubMed ID: 17674322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of outcomes of combined specific prophylaxis with the antibiotic resistant immunogenic plague pathogen strain and emergency prophylaxis with aminoglycosides in the experimental plague model in white mice].
    Ryzhko IV; Tsuraeva RI; Moldavan IA; Shcherbaniuk AI; Shut'ko AG
    Antibiot Khimioter; 2003; 48(5):15-9. PubMed ID: 12968464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of etiotropic therapy of plaque infection induced by atypical strains of F1- phenotype plaque microbe].
    Ryzhko IV; Samokhodkina ED; Tsuraeva RI; Shcherbaniuk AI; Tsetskhladze NS
    Antibiot Khimioter; 1998; 43(9):24-8. PubMed ID: 9791683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the effectiveness of antibacterial substances in treating an experimental form of bubonic plague in monkeys].
    Romanov VE; Evstigneev VI; Vasil'ev NT; Shabalin BA; Paramonov VE
    Antibiot Khimioter; 2001; 46(8):6-8. PubMed ID: 11871319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania.
    Mwengee W; Butler T; Mgema S; Mhina G; Almasi Y; Bradley C; Formanik JB; Rochester CG
    Clin Infect Dis; 2006 Mar; 42(5):614-21. PubMed ID: 16447105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.